Profile data is unavailable for this security.
About the company
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
- Revenue in USD (TTM)3.60bn
- Net income in USD1.53bn
- Incorporated2008
- Employees1.60k
- Locationargenx SELaarderhoogtweg 25AMSTERDAM 1101 EBNetherlandsNLD
- Phone+31 763030
- Websitehttps://www.argenx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Iqvia Holdings Inc | 16.31bn | 1.36bn | 31.80bn | 91.00k | 23.86 | 4.89 | 12.81 | 1.95 | 7.86 | 7.86 | 93.98 | 38.34 | 0.5739 | -- | 4.94 | -- | 4.71 | 4.69 | 6.47 | 6.14 | 33.29 | 34.29 | 8.21 | 8.18 | -- | 3.36 | 0.7034 | -- | 5.87 | 7.50 | -0.9468 | 37.27 | -0.4257 | -- |
| Insmed Inc | 447.02m | -1.18bn | 31.96bn | 1.27k | -- | 33.69 | -- | 71.50 | -6.18 | -6.18 | 2.35 | 4.45 | 0.2026 | 0.9558 | 8.31 | 351,708.90 | -53.64 | -44.83 | -63.35 | -51.79 | 76.54 | 77.08 | -264.83 | -226.78 | 4.34 | -44.87 | 0.4351 | -- | 19.17 | 21.66 | -21.91 | -- | -12.30 | -- |
| argenx SE - ADR | 3.60bn | 1.53bn | 50.69bn | 1.60k | 35.09 | -- | -- | 14.06 | 23.12 | 23.12 | 54.54 | -- | -- | -- | -- | 2,254,315.00 | -- | -7.11 | -- | -7.96 | 89.63 | -- | 42.54 | -27.22 | -- | -- | -- | -- | 78.60 | 94.61 | 382.34 | -- | 7.88 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 5.37m | 8.72% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 2.81m | 4.57% |
| Janus Henderson Investors US LLCas of 30 Sep 2025 | 2.54m | 4.13% |
| Artisan Partners LPas of 30 Sep 2025 | 2.19m | 3.55% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2025 | 1.96m | 3.18% |
| Avoro Capital Advisor LLCas of 30 Sep 2025 | 990.00k | 1.61% |
| T. Rowe Price International Ltd.as of 30 Sep 2025 | 828.78k | 1.35% |
| ClearBridge Investments LLCas of 30 Sep 2025 | 756.86k | 1.23% |
| Citadel Advisors LLCas of 30 Sep 2025 | 708.95k | 1.15% |
| RTW Investments LPas of 30 Sep 2025 | 673.50k | 1.09% |
